drugset / Trial / NCT06546150
RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
At present, there is an urgent need for new drugs for KRAS mutant tumors in clinic. Preclinical studies support the specificity, safety and anti-tumor activity of RE002. Previous similar studies suggest the feasibility of TCR-T treatment, and measures have been taken to ensure the safe administration of RE002 and the close monitoring and management of adverse events. To sum up, RE002 has controllable safety and anti-tumor activity on KRAS mutant solid tumor, which can be preliminarily studied to provide support for clinical research of patients with advanced solid tumor.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2026-04-01
- Completion
- 2027-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RE002 T cell | Cell therapy | 4e+09 cells | — |
| Subject | RE002 T cell | Cell therapy | 8e+09 cells | — |
| Subject | RE002 T cell | Cell therapy | 1.6e+10 cells | — |
Indications
No indication recorded.